Sanofi Strikes $9.1 Billion Deal to Acquire US Biopharma Firm Blueprint

Sanofi, a French pharmaceutical business, said on June 2 that it has agreed to purchase Blueprint Medicines Corporation, a biopharmaceutical company based in the United States that specialises in systemic mastocytosis, a rare immunological condition.

Sanofi would pay $129.00 per share in cash under the terms of the transaction, which translates to an equity value of about $9.1 billion. According to Paul Hudson, CEO of Sanofi, the acquisition is a strategic move ahead for the company's immunology and rare disease portfolios.

It improves Sanofi's pipeline and speeds up our development into the top immunology business in the world.

Acquisition Adding More Muscle to Sanofi’s Portfolio

The agreement will expand Sanofi's portfolio to include a promising advanced and early-stage immunology pipeline, as well as the US and EU-approved medication Ayvakit/Ayvakyt (avapritinib), which is used to treat rare immunology diseases.

According to the companies, Blueprint's well-established reputation among immunologists, dermatologists, and allergists is also anticipated to strengthen Sanofi's expanding immunology pipeline.

For advanced and indolent systemic mastocytosis, a rare immunological illness marked by the accumulation and activation of aberrant mast cells in the gastrointestinal tract, skin, bone marrow, and other organs, Ayvakit/Ayvakyt is the only licensed medication.

Along with BLU-808, a highly effective and selective oral wild-type KIT inhibitor that may be used to treat a variety of immunological disorders, the acquisition will also provide elenestinib, a next-generation treatment for systemic mastocytosis.

Contingent Value Right to Blueprint Shareholders

At the closing of the transaction, Blueprint shareholders will receive $129.00 per share in cash in addition to one non-tradeable contingent value right (CVR), which will grant the holder the right to two potential milestone payments of $2 and $4 per CVR, respectively, for the accomplishment of future development and regulatory milestones for BLU-808.

On a fully diluted basis, the transaction's entire equity value, including any future CVR payments, is roughly $9.5 billion.

Hudson said that Sanofi still has a sizable capacity for other purchases and that the deal complements recent acquisitions of other early-stage medications that continue to be the company's primary area of interest.

About Sanofi

An AI-powered biopharma firm focused on research and development, Sanofi is dedicated to enhancing people's lives and fostering remarkable growth.

With a cutting-edge pipeline that could help millions more, it claims that the company uses its profound knowledge of the immune system to develop medications and vaccines that treat and safeguard millions of people worldwide.

Its team is driven by a single goal: to improve people's lives by pursuing scientific miracles. This motivates Sanofi to advance and have a positive impact on its customers and the communities it serves by tackling the most pressing social, environmental, and healthcare issues of the recent times.